Clinical Efficacy and Safety of Yellow Oil Formulations 3 and 4 versus Indomethacin Solution in Patients with Symptomatic Osteoarthritis of the Knee: A Randomized Controlled Trial

Koonrungsesomboon, Nut; Teekachunhatean, Supanimit; Chansakaow, Sunee; Hanprasertpong, Nutthiya

doi:10.1155/2020/5782178

Cited by 9 publications

(13 citation statements)

References 57 publications

(69 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this study found that SHT extract showed good reduction in stiffness index, significantly different with day 0 and no significant difference with diclofenac. SHT extract showed different results when compared with SHT powder; in that, SHT extract showed better efficacy on stiffness reduction than SHT powder [ 5 ]. In addition, the total stiffness score of SHT extract decreased on days 14 and 28, equal to that of diclofenac.…”

Section: Discussionmentioning

confidence: 99%

“…These results indicated that SHT extract was more effective on OA knee patients than SHT powder. Both extract and powder of SHT showed no significant difference when compared with diclofenac [ 5 ].…”

Section: Discussionmentioning

confidence: 99%

“…Diclofenac was used as an active control which showed a superior effect for osteoarthritis [ 2 ]. Not only NSIADs were used for OA treatment but alternative medicine was also commonly used, including acupuncture, Thai massage, sesame oil, yellow oil, and herbal medicine [ 3 – 5 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and Safety of Sahastara Remedy Extract Capsule in Primary Knee Osteoarthritis: A Randomized Double-Blinded Active-Controlled Trial

Kakatum

Pinsornsak

Kanokkangsadal

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Sahastara (SHT) remedy is a Thai traditional medicine described in the Thai National List of Essential Medicine (NLEM) for the relief of muscle pain. The purpose of this study was to investigate the efficacy and safety of SHT remedy extract capsule for treating primary OA. A phase 2, double-blind, randomized, and controlled trial study was used to determine the clinical efficacy and safety of SHT in comparison with diclofenac for the treatment of knee OA. The outcome of reduce pain was measured from VAS, 100 meter time walk, and the WOMAC score of day 14 and day 28 which should reduce significantly when compared with day 0 and should be equal with or better than diclofenac. Blood pressure and blood chemistry values at day 14 and day 28 did not change when compared with day 0. The results found that SHT remedy ethanolic extract capsule can reduce all OA knee scores at day 14 and day 28 significantly when compared with day 0 and also no significant difference with diclofenac ( P > 0.05 ). The SHT also showed safety values on blood pressure and blood chemistry. The SHT was observed that it had no serious side effect. The results of this study are the first report of using the SHT ethanolic extract capsule in the treatment of primary osteoarthritis of the knee. It can be recommended as an anti-inflammatory herbal drug for reducing pain in knee osteoarthritis patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Safety of Sahastara Remedy Extract Capsule in Primary Knee Osteoarthritis: A Randomized Double-Blinded Active-Controlled Trial

Kakatum

Pinsornsak

Kanokkangsadal

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“… 12 Only symptomatical treatment of OA can be performed. Hence, analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) addressing pain and inflammation are the therapeutic options for OA 45 , 46 with adverse effects in long-term use. 47 NSAIDs are widely prescribed for the treatment of symptomatic OA of the knee.…”

Section: Oa Is So Far Untreatablementioning

confidence: 99%

Experimental Therapeutics for the Treatment of Osteoarthritis

Schulze‐Tanzil

2021

JEP

View full text Add to dashboard Cite

Osteoarthritis (OA) therapy remains a large challenge since no causative treatment options are so far available. Despite some main pathways contributing to OA are identified its pathogenesis is still rudimentary understood. A plethora of therapeutically promising agents are currently tested in experimental OA research to find an opportunity to reverse OA-associated joint damage and prevent its progression. Hence, this review aims to summarize novelly emerging experimental approaches for OA. Due to the diversity of strategies shown only main aspects could be summarized here including herbal medicines, nanoparticular compounds, growth factors, hormones, antibody-, cell-and extracellular vesicle (EV)-based approaches, optimized tools for joint viscosupplementation, genetic regulators such as si-or miRNAs and promising combinations. An abundant multitude of compounds obtained from plants, environmental, autologous or synthetic sources have been identified with anabolic, anti-inflammatory,-catabolic and anti-apoptotic properties. Some ubiquitous signaling pathways such as wingless and Integration site-1 (Wnt), Sirtuin, Tolllike receptor (TLR), mammalian target of rapamycin (mTOR), Nuclear Factor (NF)-κB and complement are involved in OA and addressed by them. Hyaluronan (HA) provided benefit in OA since many decades, and novel HA formulations have been developed now with higher HA content and long-term stability achieved by cross-linking suitable to be combined with other agents such as components from herbals or chemokines to attract regenerative cells. pH-or inflammation-sensitive nanoparticular compounds could serve as versatile slowrelease systems of active compounds, for example, miRNAs. Some light has been brought into the intimate regulatory network of small RNAs in the pathogenesis of OA which might be a novel avenue for OA therapy in future. Attraction of autologous regenerative cells by chemokines and exosome-based treatment strategies could also innovate OA therapy.

show abstract

“…Given the large number of people affected with osteoarthritis of the knee and societal trends in population aging and obesity [ 14 ], identifying effective and safe therapeutic options that are available in a region is viewed as a priority for sustainable development in a country [ 15 ]. In this regard, herbal medicine could be a promising approach to be employed in developing such therapeutic options [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

Clinical Efficacy and Safety of Thai Herbal Formulation‐6 in the Treatment of Symptomatic Osteoarthritis of the Knee: A Randomized‐Controlled Trial

Koonrungsesomboon

Nopnithipat

Teekachunhatean

et al. 2020

Evidence-Based Complementary and Alternative Medicine

Self Cite

View full text Add to dashboard Cite

Background. Osteoarthritis of the knee is the most common form of arthritis. Identifying effective and safe herbal formulations that are locally available is viewed as a priority for sustainable development in a region. This study aimed to evaluate the efficacy and safety of Thai herbal formulation-6 (THF-6) in comparison with oral diclofenac in patients with moderate-to-severe osteoarthritis of the knee. Methods. This randomized, double-blind, active-controlled, noninferiority trial randomly assigned patients with osteoarthritis of the knee to receive either THF-6 or diclofenac for four weeks. The primary outcome measure was the change from baseline in knee pain as measured by a 100 mm visual analog scale (VAS). Secondary outcome measures included knee stiffness, a stair climb test, the Knee Injury and Osteoarthritis Outcome Score, and safety parameters. Outcomes were assessed on a biweekly basis. Modified intention-to-treat (MITT) and perprotocol (PP) analyses were applied. Results. A total of 200 patients were enrolled of whom 175 (87.5%) were included in the MITT analysis and 153 (76.5%) in the PP analysis. The mean change in VAS pain did not differ between the two groups, and the upper limit of the two-sided 95% confidence interval (CI) for comparison between the two groups was within the prespecified margin of 10 mm for noninferiority (MITT analysis: mean difference = 0.86, 95% CI = -4.39 to 6.10, p = 0.748 ; PP analysis: mean difference = 1.98, 95% CI = -3.61 to 7.56, p = 0.486 ). Significant improvement was observed in all the efficacy parameters in both groups. Dyspepsia was the most common adverse event: 23 patients in the THF-6 group and 28 in the diclofenac group p = 0.417 . Conclusions. THF-6 offers an alternative to oral diclofenac for the short-term treatment of osteoarthritis of the knee. It was shown to be noninferior to oral diclofenac in relieving knee pain. This trial is registered with ChiCTR-IPR-15007213.

show abstract

Clinical Efficacy and Safety of Yellow Oil Formulations 3 and 4 versus Indomethacin Solution in Patients with Symptomatic Osteoarthritis of the Knee: A Randomized Controlled Trial

Cited by 9 publications

References 57 publications

Efficacy and Safety of Sahastara Remedy Extract Capsule in Primary Knee Osteoarthritis: A Randomized Double-Blinded Active-Controlled Trial

Efficacy and Safety of Sahastara Remedy Extract Capsule in Primary Knee Osteoarthritis: A Randomized Double-Blinded Active-Controlled Trial

Experimental Therapeutics for the Treatment of Osteoarthritis

Clinical Efficacy and Safety of Thai Herbal Formulation‐6 in the Treatment of Symptomatic Osteoarthritis of the Knee: A Randomized‐Controlled Trial

Contact Info

Product

Resources

About